Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 3061 Mn in 2023, growing at a CAGR of 14.3% ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...